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Abstract 
The immunosuppressant azathioprine (AZA) is widely used in the treatment of 
inflammatory bowel disease (IBD) for both inducing and maintaining remission. 
However, the adverse effects of AZA can often necessitate a dose reduction or 
discontinuation. Bone marrow suppression is one of the most serious complications 
with AZA treatment. On the other hand, some reports have suggested that neutropenia 
during AZA therapy reduced the relapse rates of IBD patients, and there have been some 
cases where eradication of the sensitized leukocytes by leukapheresis or bone marrow 
transplantation improved the IBD, which may explain the relevant role of neutropenia 
in controlling disease activity. This report describes the case of a 22-year-old male 
patient who had Crohn’s colitis and complicated perianal fistulas that required 
immunosuppression; he achieved endoscopically determined remission and showed 
accelerated mucosal healing as well as clinical remission following the AZA-induced 
pancytopenia. 
Introduction 
A rising trend in the incidence and prevalence of inflammatory bowel disease (IBD) in 
Asia has been recognized for the past two decades. The thiopurine drugs azathioprine 
(AZA) and mercaptopurine are widely used for the treatment of IBD and have proven to 
be effective in both inducing and maintaining remission of Crohn’s disease and ulcerative 
colitis; however adverse effects can occur in 9–28% of patients, and these adverse effects Case Rep Gastroenterol 2011;5:344–349 
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often necessitate a dose reduction or discontinuation. Bone marrow suppression is one 
of the most serious complications with AZA treatment. Nevertheless, some reports 
suggested that neutropenia during AZA therapy reduced the relapse rates in IBD patients 
[1, 2], and that the eradication of sensitized leukocytes, which was done by leukapheresis 
or bone marrow transplantation, improved IBD in some cases [3, 4]. This may explain the 
relevant role of neutropenia in controlling disease activity. There have also been some 
cases of ulcerative colitis with prolonged remission following AZA-induced pancytopenia 
[5, 6]. 
Case Report 
A 22-year-old man with a known history of Crohn’s colitis who had undergone fistulectomy for 
complex perianal fistula 2 years previously was admitted with a complaint of severe weight loss (25 kg 
during 2 years), diarrhea, abdominal pain and recurrent perianal tenderness. His home medications 
were mesalamine and herbal medicine. Physical exam revealed fistular openings and subcutaneous 
abscess pockets with severe tenderness on the anus and buttock. He was not able to maintain a sitting 
or supine position, so his social activity was limited. The vital signs were normal except for mild fever. 
Examination under anesthesia revealed complicated anal fistulas and perianal abscesses. On 
colonoscopy, multiple and diffuse aphthous ulcerations were noted (fig. 1). Contrast-enhanced 
computed tomography scan of the abdomen showed multifocal inflammatory wall thickening and 
thick-walled abscess pockets with the beaded appearance of subcutaneous small abscesses in the 
precoccygeal and perianal area (fig. 2, fig. 3). The Crohn’s disease activity index (CDAI) was 244. 
Abscess drainage and a seton operation were performed, then AZA was administered at a starting dose 
of 25 mg; this was increased up to 50 mg after 2 weeks. He then revisited the hospital and presented with 
high fever (39.2°C) and myalgia. On general peripheral blood test, leukocytes were 180/μl (segmented 
cells 6%), hemoglobin was 6.6 g/dl and platelets were 48,000/μl. ESR was 55 mm/h and CRP was 
24.7 mg/l. The remainder of the laboratory data was within normal limit. We immediately discontinued 
AZA and suspected pancytopenia and septicemia caused by the immunosuppressant. After 2 weeks of 
administering human recombinant granulocyte colony-stimulating factor and broad-spectrum 
antibiotic therapy, his fever subsided and the cell count fully recovered. Escherichia coli was found on 
blood culture, but it was sensitive to the antibiotics. Thiopurine methyltransferase (TPMT) was the wild 
type (*1/*1). After recovering from cytopenia, the frequency of bowel movements decreased and the 
perianal pain and oozing improved gradually. Follow-up colonoscopy was performed 3 months later 
and demonstrated diffuse fibrotic scar instead of multiple ulcerations (fig. 4). He gained 10 kg within 
6 months and is now on regular follow-up without clinical recurrence (CDAI score = 114). 
Discussion 
Bone marrow suppression is a common but potentially serious side effect of AZA 
treatment. The effect of AZA on bone marrow is largely dose-dependent. Therefore, 
a conventional immunosuppressive dose of less than 2.5 mg/kg/day causes predictable 
mild leukopenia. Rarely however, sudden, severe and unexpected myelosuppression, 
which is possibly idiosyncratic, has also been reported when low to moderate doses 
(<2 mg/kg/day) of the drug were used. In these cases, the cytopenic patients are 
vulnerable to the development of sepsis that necessitates hospital admission for intensive 
care. 
Immunosuppression by AZA is supposed to be mediated through its effects on 
lymphocytes. However, the preferential suppression of neutrophils develops when 
leukopenia occurs, which suggests that AZA’s antiinflammatory effects are mediated 
through its effects on neutrophils as well [7]. In fact, clinical relapse of IBD is 
characterized by increased neutrophil migration into the intestine [8]. Therefore, Case Rep Gastroenterol 2011;5:344–349 
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neutropenia following AZA can probably affect the clinical improvement, theoretically. 
Moreover, some reports have described cases of ulcerative colitis with prolonged 
remission following pancytopenia. Burke et al. reported prolonged remission in excess of 
4 years following induced pancytopenia, where 3 of the 4 patients who developed severe 
neutropenia remained in remission for up to 21 months following that episode [6]. 
The mechanism that can explain this clinical improvement is unclear. First, given that 
altered host immunity plays an important role in IBD activity, it is possible that this 
patient’s host immunity was reset following the pancytopenia caused by AZA. According 
to one report that analyzed the course of patients with Crohn’s disease and ulcerative 
colitis and who underwent allogeneic stem cell transplantation for myeloid leukemia and 
myelodysplastic syndrome, 10 of 11 patients showed no IBD activity after stem cell 
transplantation, and the colonoscopy after complete discontinuation of prophylactic 
posttransplant immunosuppression revealed no pathologic findings [3]. Second, the 
possible benefit of granulocyte macrophage colony-stimulating factor (GM-CSF) can be 
hypothesized. Dieckgraefe and Korzenik investigated the safety and possible benefit of 
GM-CSF for the treatment of 15 patients with moderate to severe Crohn’s disease. None 
of the patients had worsening of their disease. All 15 patients had a significant decrease in 
mean CDAI score during treatment [9]. Third, the original bowel flora is temporarily 
altered after total gut decontamination and long-term antibacterial treatment. Therefore, 
the most likely theory seems to be the modification of a genetically determined immune 
abnormality that is responsible for the chronic intestinal inflammation by the reset of the 
immune system or modification of an altered microbial environment. However, it is 
unclear whether this mechanism can affect the long-term clinical course. 
Some studies have reported that TPMT genotype or activity does not predict 
the development of AZA-induced myelotoxicity [10–12]. On the other hand, some 
reports have suggested a substantial correlation between low enzyme activity and 
the development of myelotoxicity [13, 14]. Colombel et al. reported that assessment of 
the TPMT genotype or activity can reduce the risk of myelotoxicity in approximately 
one-third of patients [15]. In our case, the TPMT was the wild type and this result raised 
doubts whether TPMT can be a reasonable screening test to identify patients with a high 
risk of severe myelotoxicity due to an inherited deficiency of TPMT activity. 
In conclusion, we report here a patient who had Crohn’s colitis and complicated 
perianal fistulas that required immunosuppression, and who achieved endoscopically 
determined remission that showed accelerated mucosal healing as well as clinical 
remission after AZA-induced pancytopenia. 
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Fig. 1. Colonoscopy demonstrated multiple longitudinal aphthous ulcerations with edematous 
mucosal inflammation. 
 
 
 
Fig. 2. Contrast-enhanced abdominal CT scan showed multifocal inflammatory colonic wall 
thickening on the ascending colon (arrow).  
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Fig. 3. Contrast-enhanced abdominal CT scan showed thick-walled abscess pockets in the 
precoccygeal area (arrow) and mutiple subcutaneous small abscesses with a beaded appearance. 
 
 
 
Fig. 4. Follow-up colonoscopy after recovery of pancytopenia demonstrated disappearance of the 
multiple active aphthous ulcerations; diffuse fibrotic scar formation (suggesting accelerated mucosal 
healing) was noted instead. 
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